Breast Cancer

Breast cancer is the most common cancer in women globally. Major treatment advances include CDK4/6 inhibitors for HR+ disease, HER2-targeted therapies, PARP inhibitors for BRCA-mutated tumors, immune checkpoint inhibitors for TNBC, and a new generation of antibody-drug conjugates.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Breast Cancer

• Palbociclib (Ibrance) — CDK4/6 Inhibitor
• Ribociclib (Kisqali) — CDK4/6 Inhibitor
• Abemaciclib (Verzenio) — CDK4/6 Inhibitor
• Trastuzumab (Herceptin) — Monoclonal Antibody
• Trastuzumab deruxtecan (Enhertu) — Antibody-Drug Conjugate
• Trastuzumab Emtansine (T-DM1) (Kadcyla) — Antibody-Drug Conjugate
• Pertuzumab (Perjeta) — Monoclonal Antibody
• Sacituzumab govitecan (Trodelvy) — Antibody-Drug Conjugate
• Datopotamab deruxtecan-dlnk (Datroway) — Antibody-Drug Conjugate
• Olaparib (Lynparza) — PARP Inhibitor
• Tucatinib (Tukysa) — Tyrosine Kinase Inhibitor
• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Elacestrant (Orserdu) — Other
• Imlunestrant (Inluriyo) — Hormonal Agent
• Inavolisib (Itovebi) — PI3K Inhibitor
• Fulvestrant (Faslodex) — Hormonal Agent
• Letrozole (Femara) — Hormonal Agent
• Anastrozole (Arimidex) — Hormonal Agent
• Capecitabine (Xeloda) — Antimetabolite